•
Mar 31, 2021
Precigen Q1 2021 Earnings Report
Precigen's financial performance in Q1 2021 reflected progress in clinical programs and strategic scaling down of operations.
Key Takeaways
Precigen reported a net loss of $21.8 million, with a decrease in total revenues by $5.3 million compared to the prior year. The company highlighted progress in its clinical programs and the initiation of a Phase 1 study for PRGN-2012.
Advanced clinical programs, including UltraCAR-T trials and PRGN-2009, progressed as planned.
Initiated Phase 1 clinical trial of PRGN-2012 AdenoVerse immunotherapy.
Received orphan drug designation from the US FDA for PRGN-2012 in patients with recurrent respiratory papillomatosis (RRP).
Total revenues decreased by $5.3 million, primarily due to a decrease in collaboration and licensing revenues.
Precigen
Precigen
Forward Guidance
Precigen is on track to achieve its stated 2021 milestones.